Proposed Collection; 60-Day Comment Request; Stakeholder Measures and Advocate Forms at the National Cancer Institute (NCI), 46894-46895 [2024-11897]
Download as PDF
<![CDATA[
46894
Federal Register / Vol. 89, No. 105 / Thursday, May 30, 2024 / Notices
Disability Accommodations: All IACC
Full Committee Meetings provide
Closed Captioning through the NIH
videocast website. Individuals whose
full participation in the meeting will
require special accommodations (e.g.,
sign language or interpreting services,
etc.) must submit a request to the
Contact Person listed on the notice at
least seven (7) business days prior to the
meeting. Such requests should include
a detailed description of the
accommodation needed and a way for
the IACC to contact the requester if
more information is needed to fill the
request. Special requests should be
made at least seven (7) business days
prior to the meeting; last-minute
requests may be made but may not be
possible to accommodate.
Security: During the check-in process,
attendees will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit. Pre-registration is
recommended. Seats will be on a first
come, first served basis, with expedited
check-in for those who are preregistered. Meeting schedule subject to
change.
More Information: Information about
the IACC is available on the website:
https://www.iacc.hhs.gov.
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–11848 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Sickle Cell Disease
Advisory Committee.
The meeting will be held as a virtual
meeting and will be open to the public
as indicated below. Individuals who
plan to view the virtual meeting and
need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting.
Name of Committee: Sickle Cell Disease
Advisory Committee.
Date: July 23, 2024.
Time: 3:00 p.m. to 5:00 p.m.
VerDate Sep<11>2014
20:03 May 29, 2024
Jkt 262001
Agenda: NHLBI Sickle Cell Disease
Program Updates.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
The event is free and open to the public,
however, registration is required. Please use
this link to register: https://
nih.zoomgov.com/webinar/register/WN_
RZK8GeENQWO9DmGH3bBFnQ.
Contact Person: Julie A. Panepinto, MD,
MSPH, DFO/Executive Secretary SCDAC,
Director, Division of Blood Diseases and
Resources, 6701 Rockledge Drive, Suite 9166,
Bethesda, MD 20892, (301) 435–0080,
NHLBIDBDRGrantResource@nhlbi.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/advisory-and-peerreview-committees/nhlbi-sickle-cell-diseaseadvisory-committee, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–11856 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment
Request; Stakeholder Measures and
Advocate Forms at the National Cancer
Institute (NCI)
AGENCY:
National Institutes of Health,
HHS.
ACTION:
PO 00000
Notice.
Frm 00042
Fmt 4703
Sfmt 4703
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health, National
Cancer Institute (NCI) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Amy Williams, Director of the
Office of Advocacy Relations (OAR),
NCI, NIH, 31 Center Drive, Bldg. 31,
Room 10A28, MSC 2580, Bethesda, MD
20892, call non-toll-free number 240–
781–3406, or email your request,
including your address, to
amy.williams@nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
SUPPLEMENTARY INFORMATION: Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Proposed Collection Title:
Stakeholder Measures and Advocate
Forms at the National Cancer Institute
(NCI), 0925–0774, Expiration Date10/
31/2024, REVISION, National Cancer
Institute (NCI), National Institutes of
Health (NIH).
Need and Use of Information
Collection: This is a request for OMB to
approve the revision of the collection
titled, ‘‘Stakeholder Measures and
SUMMARY:
E:\FR\FM\30MYN1.SGM
30MYN1
46895
Federal Register / Vol. 89, No. 105 / Thursday, May 30, 2024 / Notices
Advocate Forms at the National Cancer
Institute (NCI)’’ for an additional three
years of data collection. The Office of
Advocacy Relations (OAR) disseminates
cancer-related information to a variety
of stakeholders, seeks input and
feedback, and facilitates collaboration to
advance NCI’s authorized programs. It is
beneficial for NCI, through the OAR, to
pretest strategies, concepts, activities
and materials while they are under
development. Additionally,
administrative forms are a necessary
part of collecting demographic
information and areas of interest for
advocates. Since OAR is responsible for
matching advocates to NCI programs
and initiatives across the cancer
continuum, it is necessary to measure
the satisfaction of both internal and
external stakeholders with this
collaboration. This customer satisfaction
research helps ensure the relevance,
utility, and appropriateness of the many
initiatives and products that OAR and
NCI produce. Past research has enabled
OAR to monitor stakeholder trends,
design and develop materials based on
user feedback, assess the impact of
activities, and improve service delivery.
Primary users are internal with some
advocates providing contact
information, demographics and prior
advocacy experience via a link provided
to them to input their data.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
17.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Advocates Survey ..............................
Requestor Survey ...............................
Profile Completion ..............................
6
6
30
1
1
1
5/60
5/60
30/60
1
1
15
.............................................................
....................
42
........................
17
Type of respondent
Form name
Individuals ...........................................
Individuals ...........................................
Individuals ...........................................
Total .............................................
Dated: May 24, 2024
Diane Kreinbrink,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
[FR Doc. 2024–11897 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
ddrumheller on DSK120RN23PROD with NOTICES1
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Clinical and Data
Coordinating Center Applications for NCCIH
Multi-Site Clinical Trials of Mind and Body
Interventions.
Date: June 27, 2024.
Time: 9:30 a.m. to 1:30 p.m.
VerDate Sep<11>2014
20:03 May 29, 2024
Jkt 262001
Agenda: To review and evaluate grant
applications.
Place: National Center for Complementary
and Integrative, Democracy II, 6707
Democracy Blvd., Bethesda, MD 20892.
Contact Person: Mei Qin, MD, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, Division of Extramural Activities,
NCCIH/NIH, 6707 Democracy Blvd., Suite
401, Bethesda, MD 20892, mei.qin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: May 23, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–11851 Filed 5–29–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. to achieve
expeditious commercialization of
results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Average time
per response
( in hours)
Total annual
burden hour
by emailing the licensing contact
Michael Shmilovich, Esq, MS, CLP;
301–435–5019; michael.shmilovich@
nih.gov at the National Heart, Lung, and
Blood, Office of Technology Transfer
and Development Office of Technology
Transfer, 31 Center Drive, Room 4A25,
MSC2479, Bethesda, MD 20892–2479. A
signed Confidential Disclosure
Agreement may be required to receive
any unpublished information.
SUPPLEMENTARY INFORMATION: This
notice is in accordance with 35 U.S.C.
209 and 37 CFR part 404. Technology
description follows.
Next generation MRI platform Signal
Amplification by Reversible Exchange
(SABRE) hyperpolarization:
Hyperpolarized magnetic resonance
imaging (MRI) is an emerging molecular
imaging method for metabolic imaging
for detecting cancer, cardiovascular
disease, stroke, and traumatic brain
injury and monitoring therapy with no
Gadolinium or Iron. Available for
licensing and commercial development
is a patent estate covering a
perfluorinated single amplification by
reversible exchange (SABRE) catalyst for
generating MRI agents that includes a dblock element and a perfluorinated
ligand hyperpolarized substrate
comprising a 1⁄2 spin nucleus or nuclei
using the perfluorinated SABRE
catalysts, and isolating the resulting
hyperpolarized substrate for
administration. The invention also
provides methods for separating a
hyperpolarized substrate from the
SABRE catalyst and/or hyperpolarized
SABRE catalyst complex containing a
E:\FR\FM\30MYN1.SGM
30MYN1
]]>Agencies
[Federal Register Volume 89, Number 105 (Thursday, May 30, 2024)]
[Notices]
[Pages 46894-46895]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11897]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; Stakeholder Measures
and Advocate Forms at the National Cancer Institute (NCI)
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the requirement of the Paperwork Reduction
Act of 1995 to provide opportunity for public comment on proposed data
collection projects, the National Institutes of Health, National Cancer
Institute (NCI) will publish periodic summaries of proposed projects to
be submitted to the Office of Management and Budget (OMB) for review
and approval.
DATES: Comments regarding this information collection are best assured
of having their full effect if received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data
collection plans and instruments, submit comments in writing, or
request more information on the proposed project, contact: Amy
Williams, Director of the Office of Advocacy Relations (OAR), NCI, NIH,
31 Center Drive, Bldg. 31, Room 10A28, MSC 2580, Bethesda, MD 20892,
call non-toll-free number 240-781-3406, or email your request,
including your address, to [email protected]. Formal requests for
additional plans and instruments must be requested in writing.
SUPPLEMENTARY INFORMATION: Section 3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires: written comments and/or suggestions
from the public and affected agencies are invited to address one or
more of the following points: (1) Whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) The accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) Ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) Ways
to minimizes the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Proposed Collection Title: Stakeholder Measures and Advocate Forms
at the National Cancer Institute (NCI), 0925-0774, Expiration Date10/
31/2024, REVISION, National Cancer Institute (NCI), National Institutes
of Health (NIH).
Need and Use of Information Collection: This is a request for OMB
to approve the revision of the collection titled, ``Stakeholder
Measures and
[[Page 46895]]
Advocate Forms at the National Cancer Institute (NCI)'' for an
additional three years of data collection. The Office of Advocacy
Relations (OAR) disseminates cancer-related information to a variety of
stakeholders, seeks input and feedback, and facilitates collaboration
to advance NCI's authorized programs. It is beneficial for NCI, through
the OAR, to pretest strategies, concepts, activities and materials
while they are under development. Additionally, administrative forms
are a necessary part of collecting demographic information and areas of
interest for advocates. Since OAR is responsible for matching advocates
to NCI programs and initiatives across the cancer continuum, it is
necessary to measure the satisfaction of both internal and external
stakeholders with this collaboration. This customer satisfaction
research helps ensure the relevance, utility, and appropriateness of
the many initiatives and products that OAR and NCI produce. Past
research has enabled OAR to monitor stakeholder trends, design and
develop materials based on user feedback, assess the impact of
activities, and improve service delivery. Primary users are internal
with some advocates providing contact information, demographics and
prior advocacy experience via a link provided to them to input their
data.
OMB approval is requested for 3 years. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 17.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average time
Type of respondent Form name Number of responses per per response ( Total annual
respondents respondent in hours) burden hour
----------------------------------------------------------------------------------------------------------------
Individuals.................... Advocates Survey.. 6 1 5/60 1
Individuals.................... Requestor Survey.. 6 1 5/60 1
Individuals.................... Profile Completion 30 1 30/60 15
------------------------------------------------------------
Total...................... .................. ........... 42 .............. 17
----------------------------------------------------------------------------------------------------------------
Dated: May 24, 2024
Diane Kreinbrink,
Project Clearance Liaison, National Cancer Institute, National
Institutes of Health.
[FR Doc. 2024-11897 Filed 5-29-24; 8:45 am]
BILLING CODE 4140-01-P
